2024 APPlexus Bispecific Antibodies Heme

CE

Redefining Precision Therapeutics in Hematologic Malignancies: Current Practice and Next Questions on Bispecific Antibodies

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurses: 1.00 Nursing contact hour

Released: June 05, 2024

Expiration: December 30, 2024

Sherry Adkins
Sherry Adkins, MSN, ANP-C, FAAN
Beth Faiman
Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Presurvey 1: In the pivotal phase I/II MajesTEC-1 trial evaluating teclistamab in patients with R/R MM, which of the following was reported? 

2.

Presurvey 2: Your patient with R/R MM is starting treatment with a bispecific antibody, but he is concerned about getting transportation to the treatment facility. Which of the following approved agents would be most convenient for him based on the availability of initial biweekly dosing after completing step-up dosing? 

3.

Presurvey 3: For a patient with DLBCL receiving a CD3 x CD20 bispecific antibody with grade 2 CRS, in addition to supportive care, which of the following would you recommend as the first step for managing this AE?